Lisa Shea: Working Toward Better Outcomes in High-Risk Pregnancy
Lisa Shea, Director, Global Patient Advocacy and Engagement – Rare Autoantibody at Johnson & Johnson, shared a post on LinkedIn:
“This week, I’m proud to recognize High Risk Pregnancy Awareness Week and the maternal-fetal medicine and OBGYN communities working to support families facing complex pregnancies.
At Johnson & Johnson Innovative Medicine, we’re proud to be advancing the field of maternal-fetal immunology, with a focus on driving awareness of hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Together with the broader patient, prenatal diagnostic, and healthcare communities, we are working toward solutions that meet the real needs of individuals and their families navigating high-risk pregnancies, including those impacted by alloantibody diseases like HDFN and FNAIT.”
The Society for Maternal-Fetal Medicine shared a post on LinkedIn:
“June 1- 8 is High Risk Pregnancy Awareness Week!
The week is more than an awareness initiative, it’s a movement to transform the conversation around high-risk pregnancy care.
What is a high-risk pregnancy?
A pregnancy can be classified as high-risk for many reasons, a chronic condition like diabetes or high blood pressure, a complication that develops during pregnancy like preeclampsia or preterm labor, or concerns about fetal health like a genetic disorder or birth defect.”
Stay updated with Hemostasis Today.
-
Jun 5, 2026, 14:08Kane O’Malley: Challenging Established Sample Handling Practices in Coagulation Diagnostics
-
Jun 5, 2026, 14:00Thasleena Kayyalikkal: The Diagnostic Power of the Peripheral Blood Smear
-
Jun 5, 2026, 12:17Our CEO, Dr Lisa Murphy On The Barriers Faced by Stroke Survivors on The One Year On Podcast – Stroke Foundation
-
Jun 5, 2026, 12:14Hear from Dr. Jeyaraj Pandian on Why WSC2026 Is a Defining Moment for The Global Stroke Community – WSO
-
Jun 5, 2026, 12:04Anna Gardin: Catch Up on the WSO GENESIS Webinar and Join the Discussion on Gender Equity
-
Jun 5, 2026, 11:59Emma Urlings: A Novel Thrombin Generation Assay for Sensitive Emicizumab Monitoring
-
Jun 5, 2026, 09:58Evaluating Anti-Xa Targets and Outcomes in Arterial Interventions – JTH
-
Jun 5, 2026, 08:27Morten Thaysen Andersen: Platelet Glycobiology and The Importance of FUT8 for Platelet Function
-
Jun 5, 2026, 08:10Michael Ertl: Air Pollution and Stroke – Which Patients Are Particularly at Risk?